Combining 3-D Quantitative Structure-Activity Relationship with Ligand Based and Structure Based Alignment Procedures for in Silico Screening of New Hepatitis C Virus NS5B Polymerase Inhibitors

The viral NS5B RNA-dependent RNA-polymerase (RdRp) is one of the best-studied and promising targets for the development of novel therapeutics against hepatitis C virus (HCV). Allosteric inhibition of this enzyme has emerged as a viable strategy toward blocking replication of viral RNA in cell based systems. Herein, we describe how the combination of a complete computational procedure together with biological studies led to the identification of novel molecular scaffolds, hitherto untested toward NS5B polymerase. Structure based 3-D quantitative structure-activity relationship (QSAR) models were generated employing NS5B non-nucleoside inhibitors (NNIs), whose bound conformations were readily available from the protein database (PDB). These were grouped into two training sets of structurally diverse NS5B NNIs, based on their binding to the enzyme thumb (15 NNIs) or palm (10 NNIs) domains. Ligand based (LB) and structure based (SB) alignments were rigorously investigated to assess the reliability on the correct molecular alignment for unknown binding mode modeled compounds. Both Surflex and Autodock programs were able to reproduce with minimal errors the experimental binding conformations of 24 experimental NS5B allosteric inhibitors. Eighty-one (thumb) and 223 (palm) modeled compounds taken from literature were LB and SB aligned and used as external validation sets for the development of 3-D QSAR models. Low error of prediction proved the 3-D QSARs to be useful scoring functions for the in silico screening procedure. Finally, the virtual screening of the NCI Diversity Set led to the selection for enzymatic assays of 20 top-scoring molecules for each final model. Among the 40 selected molecules, preliminary data yielded four derivatives exhibiting IC(50) values ranging between 45 and 75 microM. Binding mode analysis of hit compounds within the NS5B polymerase thumb domain showed that one of them, NSC 123526, exhibited a docked conformation which was in good agreement with the thumb training set most active compound (6).

[1]  Roger J.-B. Wets,et al.  Minimization by Random Search Techniques , 1981, Math. Oper. Res..

[2]  Meitian Wang,et al.  Non-nucleoside inhibitors binding to hepatitis C virus NS5B polymerase reveal a novel mechanism of inhibition. , 2006, Journal of molecular biology.

[3]  G. Cruciani,et al.  Generating Optimal Linear PLS Estimations (GOLPE): An Advanced Chemometric Tool for Handling 3D‐QSAR Problems , 1993 .

[4]  Neerja Kaushik-Basu,et al.  Identification and characterization of coumestans as novel HCV NS5B polymerase inhibitors , 2008, Nucleic acids research.

[5]  Uwe Koch,et al.  Recent progress in the development of inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. , 2007, Current topics in medicinal chemistry.

[6]  Ajay N. Jain,et al.  Physical binding pocket induction for affinity prediction. , 2009, Journal of medicinal chemistry.

[7]  Holger Gohlke,et al.  The Amber biomolecular simulation programs , 2005, J. Comput. Chem..

[8]  Volker Brass,et al.  Recent developments in target identification against hepatitis C virus , 2004, Expert opinion on therapeutic targets.

[9]  M. Houghton,et al.  Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. , 1989, Science.

[10]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[11]  Jeffrey A Pfefferkorn,et al.  Inhibitors of HCV NS5B polymerase. Part 1: Evaluation of the southern region of (2Z)-2-(benzoylamino)-3-(5-phenyl-2-furyl)acrylic acid. , 2005, Bioorganic & medicinal chemistry letters.

[12]  Gary Larson,et al.  Novel thiazolones as HCV NS5B polymerase allosteric inhibitors: Further designs, SAR, and X-ray complex structure. , 2007, Bioorganic & medicinal chemistry letters.

[13]  Neerja Kaushik-Basu,et al.  Thiazolidinones : a novel class of hepatitis C virus NS 5 B polymerase inhibitors , 2008 .

[14]  J. Hoofnagle,et al.  Mechanism of action of interferon and ribavirin in treatment of hepatitis C , 2005, Nature.

[15]  Garland R Marshall,et al.  Modulating G-protein coupled receptor/G-protein signal transduction by small molecules suggested by virtual screening. , 2008, Journal of medicinal chemistry.

[16]  Meitian Wang,et al.  Non-nucleoside Analogue Inhibitors Bind to an Allosteric Site on HCV NS5B Polymerase , 2003, The Journal of Biological Chemistry.

[17]  Fabrizio Manetti,et al.  HIV-reverse transcriptase inhibition: inclusion of ligand-induced fit by cross-docking studies. , 2005, Journal of medicinal chemistry.

[18]  Uwe Koch,et al.  Allosteric inhibition of the hepatitis C virus NS5B RNA dependent RNA polymerase. , 2006, Infectious disorders drug targets.

[19]  George Burton,et al.  Identification of small molecule inhibitors of the hepatitis C virus RNA-dependent RNA polymerase from a pyrrolidine combinatorial mixture. , 2005, Bioorganic & medicinal chemistry letters.

[20]  A. Mai,et al.  3-(4-Aroyl-1-methyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors. 3. Discovery of novel lead compounds through structure-based drug design and docking studies. , 2004, Journal of medicinal chemistry.

[21]  R. Shoemaker,et al.  Identification of polymerase and processivity inhibitors of vaccinia DNA synthesis using a stepwise screening approach. , 2008, Antiviral research.

[22]  Hui Li,et al.  Identification and structure-based optimization of novel dihydropyrones as potent HCV RNA polymerase inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[23]  David S. Goodsell,et al.  Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998, J. Comput. Chem..

[24]  G. Cruciani,et al.  Comparative molecular field analysis using GRID force-field and GOLPE variable selection methods in a study of inhibitors of glycogen phosphorylase b. , 1994, Journal of medicinal chemistry.

[25]  Ricardo Macarron,et al.  Identification and Biological Characterization of Heterocyclic Inhibitors of the Hepatitis C Virus RNA-dependent RNA Polymerase* , 2002, The Journal of Biological Chemistry.

[26]  J. Hoofnagle,et al.  Hepatitis C: The clinical spectrum of disease , 1997, Hepatology.

[27]  Yvonne Jones,et al.  High resolution structures of HIV-1 RT from four RT–inhibitor complexes , 1995, Nature Structural Biology.

[28]  S. Wold,et al.  Comparative molecular field analysis , 1991 .

[29]  Gary Larson,et al.  Thiazolone-acylsulfonamides as novel HCV NS5B polymerase allosteric inhibitors: convergence of structure-based drug design and X-ray crystallographic study. , 2007, Bioorganic & medicinal chemistry letters.

[30]  Ajay N. Jain,et al.  Ligand-based structural hypotheses for virtual screening. , 2004, Journal of medicinal chemistry.

[31]  M. Alter,et al.  Epidemiology of Hepatitis C: Geographic Differences and Temporal Trends , 2000, Seminars in liver disease.

[32]  M. Fried,et al.  Side effects of therapy of hepatitis C and their management , 2002, Hepatology.

[33]  Robert A. Love,et al.  Crystallographic Identification of a Noncompetitive Inhibitor Binding Site on the Hepatitis C Virus NS5B RNA Polymerase Enzyme , 2003, Journal of Virology.

[34]  Denis Labrecque,et al.  Discovery of thiophene-2-carboxylic acids as potent inhibitors of HCV NS5B polymerase and HCV subgenomic RNA replication. Part 1: Sulfonamides. , 2004, Bioorganic & medicinal chemistry letters.

[35]  Ajay N. Jain,et al.  Robust ligand-based modeling of the biological targets of known drugs. , 2006, Journal of medicinal chemistry.

[36]  R. Cramer,et al.  Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. , 1988, Journal of the American Chemical Society.

[37]  P. Goodford A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. , 1985, Journal of medicinal chemistry.

[38]  Jonathan B. Chaires,et al.  Discovery of novel triple helical DNA intercalators by an integrated virtual and actual screening platform , 2009, Nucleic acids research.

[39]  R. De Francesco,et al.  Advances in the development of new therapeutic agents targeting the NS3-4A serine protease or the NS5B RNA-dependent RNA polymerase of the hepatitis C virus. , 2007, Advanced drug delivery reviews.

[40]  F. Rey,et al.  Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[41]  Charles A. Lesburg,et al.  Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site , 1999, Nature Structural Biology.

[42]  Dashyant Dhanak,et al.  3-(1,1-dioxo-2H-(1,2,4)-benzothiadiazin-3-yl)-4-hydroxy-2(1H)-quinolinones, potent inhibitors of hepatitis C virus RNA-dependent RNA polymerase. , 2006, Journal of medicinal chemistry.

[43]  Darius Bilimoria,et al.  Discovery of thiophene-2-carboxylic acids as potent inhibitors of HCV NS5B polymerase and HCV subgenomic RNA replication. Part 2: tertiary amides. , 2004, Bioorganic & medicinal chemistry letters.

[44]  D S Goodsell,et al.  Automated docking of flexible ligands: Applications of autodock , 1996, Journal of molecular recognition : JMR.

[45]  Peter A. Kollman,et al.  AMBER, a package of computer programs for applying molecular mechanics, normal mode analysis, molecular dynamics and free energy calculations to simulate the structural and energetic properties of molecules , 1995 .

[46]  N. Walker,et al.  SAR and mode of action of novel non-nucleoside inhibitors of hepatitis C NS5b RNA polymerase. , 2006, Journal of medicinal chemistry.

[47]  M. Pastor,et al.  A strategy for the incorporation of water molecules present in a ligand binding site into a three-dimensional quantitative structure--activity relationship analysis. , 1997, Journal of medicinal chemistry.

[48]  Lawrence C Kuo,et al.  Inhibition of Hepatitis C Virus RNA Replication by 2′-Modified Nucleoside Analogs* , 2003, The Journal of Biological Chemistry.

[49]  Satoru Ikeda,et al.  Discovery of conformationally constrained tetracyclic compounds as potent hepatitis C virus NS5B RNA polymerase inhibitors. , 2006, Journal of medicinal chemistry.

[50]  Giovanni Migliaccio,et al.  Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase. , 2003, Antiviral research.

[51]  M Pastor,et al.  Smart region definition: a new way to improve the predictive ability and interpretability of three-dimensional quantitative structure-activity relationships. , 1997, Journal of medicinal chemistry.

[52]  David Haigh,et al.  Optimization of novel acyl pyrrolidine inhibitors of hepatitis C virus RNA-dependent RNA polymerase leading to a development candidate. , 2007, Journal of medicinal chemistry.

[53]  S. Wold,et al.  PLS: Partial Least Squares Projections to Latent Structures , 1993 .

[54]  Darius Bilimoria,et al.  Identification of N,N-disubstituted phenylalanines as a novel class of inhibitors of hepatitis C NS5B polymerase. , 2003, Journal of medicinal chemistry.

[55]  Gary Larson,et al.  Structure-based design of a novel thiazolone scaffold as HCV NS5B polymerase allosteric inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[56]  Krzysztof Kuczera,et al.  Are L-adenosine and its derivatives substrates for S-adenosyl-L-homocysteine hydrolase? , 2005, Journal of medicinal chemistry.

[57]  Maurizio Botta,et al.  A Multidisciplinary Approach for the Identification of Novel HIV‐1 Non‐Nucleoside Reverse Transcriptase Inhibitors: S‐DABOCs and DAVPs , 2008, ChemMedChem.

[58]  Uwe Koch,et al.  Interdomain Communication in Hepatitis C Virus Polymerase Abolished by Small Molecule Inhibitors Bound to a Novel Allosteric Site* , 2005, Journal of Biological Chemistry.

[59]  Nahum Sonenberg,et al.  Hepatitis C therapeutics: current status and emerging strategies , 2002, Nature Reviews Drug Discovery.

[60]  Conrad C. Huang,et al.  Tools for integrated sequence-structure analysis with UCSF Chimera , 2006, BMC Bioinformatics.

[61]  Richard Nugent,et al.  Inhibitors of HCV NS5B polymerase. Part 2: Evaluation of the northern region of (2Z)-2-benzoylamino-3-(4-phenoxy-phenyl)-acrylic acid. , 2005, Bioorganic & medicinal chemistry letters.

[62]  N. Walker,et al.  Novel inhibitors of hepatitis C virus RNA-dependent RNA polymerases. , 2006, Journal of molecular biology.

[63]  C. Rice,et al.  Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties. , 2000, Current topics in microbiology and immunology.

[64]  Rajiv Chopra,et al.  Discovery of proline sulfonamides as potent and selective hepatitis C virus NS5b polymerase inhibitors. Evidence for a new NS5b polymerase binding site. , 2006, Journal of medicinal chemistry.

[65]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..